Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lipocine Inc. (LPCN:NASDAQ), powered by AI.
Lipocine Inc. is currently trading at $2.26. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Lipocine Inc. on Alpha Lenz.
Lipocine Inc.'s P/E ratio is -1.3.
“Lipocine Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -54.3%. 3Y revenue CAGR of 58.1% highlights clear growth momentum.”
Ask for details →Lipocine Inc. is a pharmaceutical company specializing in the development and commercialization of innovative products through its proprietary oral drug delivery technology. The primary function of Lipocine Inc. is to improve patient compliance by converting drugs traditionally administered via injection into oral dosage forms. This technology enhances the absorption and bioavailability of oral medications, thereby addressing common challenges faced in drug delivery. Lipocine Inc.'s portfolio includes products targeting testosterone deficiency and metabolic disorders, with some in advanced stages of clinical trials. Operating at the intersection of the pharmaceutical and biotechnology sectors, the company plays a vital role in advancing therapeutic solutions for endocrine and metabolic ailments. Lipocine's innovations hold significant market potential, as they aim to create more patient-friendly therapeutic options, which can lead to increased adoption and market acceptance. Headquartered in Salt Lake City, Utah, Lipocine Inc. continues to explore strategic partnerships to expand its reach and impact within the healthcare industry.
“Lipocine Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -54.3%. 3Y revenue CAGR of 58.1% highlights clear growth momentum.”
Ask for details →Lipocine Inc. (ticker: LPCN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 16 employees. Market cap is $12M.
The current price is $2.26 with a P/E ratio of -1.28x and P/B of 0.85x.
ROE is -54.28% and operating margin is -524.69%. Annual revenue is $2M.